Symbols / AEON $0.92 +0.81% AEON Biopharma, Inc.
AEON Chart
About
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 23.21M |
| Enterprise Value | 54.98M | Income | -39.22M | Sales | — |
| Book/sh | -4.54 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 0.33 | Forward P/E | -1.33 | PEG | — |
| P/S | — | P/B | -0.20 | P/C | — |
| EV/EBITDA | -3.39 | EV/Sales | — | Quick Ratio | 0.44 |
| Current Ratio | 0.49 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.95 | EPS next Y | -0.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 17:00 | ROA | -234.17% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 25.30M |
| Shs Float | 9.82M | Short Float | 1.10% | Short Ratio | 3.67 |
| Short Interest | — | 52W High | 1.45 | 52W Low | 0.38 |
| Beta | — | Avg Volume | 141.24K | Volume | 21.67K |
| Target Price | $6.70 | Recom | Strong_buy | Prev Close | $0.91 |
| Price | $0.92 | Change | 0.81% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.70
Mean price target
2. Current target
$0.92
Latest analyst target
3. DCF / Fair value
$-11.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.92
Low
$5.00
High
$8.40
Mean
$6.70
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-08 | reit | Aegis Capital | Buy → Buy | $7 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-14 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-08-18 | init | HC Wainwright & Co. | — → Buy | $18 |
- New AEON finance chief gets stock awards tied to NYSE compliance - Stock Titan Fri, 03 Apr 2026 20
- Special stock report: AEON (5.24% → 4.78%) by Sumitomo Mitsui Trust Bank, etc. - Moomoo Mon, 06 Apr 2026 04
- AEON Biopharma Receives Additional NYSE American Noncompliance Notice - TipRanks Fri, 03 Apr 2026 20
- AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill hu, 02 Apr 2026 07
- AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan Fri, 03 Apr 2026 20
- AEON REIT Investment Corporation (3292.T) Stock Price, News, Quote & History - Yahoo! Finance Canada Wed, 01 Apr 2026 03
- AEON faces an August 2026 cutoff: The countdown to delisting intensifies as the stock battles to remain listed - bitget.com Fri, 03 Apr 2026 05
- Aeon Biopharma stock falls after FDA meeting and debt restructuring - Investing.com Wed, 21 Jan 2026 08
- AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan Fri, 03 Apr 2026 22
- Aeon Co. (M) Bhd.'s (KLSE:AEON) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - Yahoo Finance Sun, 28 Sep 2025 07
- AEON Biopharma Faces Delisting Clock: Can Compliance Catalyst Trigger Sharp Reversal? - bitget.com Fri, 03 Apr 2026 05
- Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year - Yahoo Finance Sun, 14 Dec 2025 08
- AEON Biopharma (NYSE American: AEON) faces added NYSE equity noncompliance risk - Stock Titan Fri, 03 Apr 2026 20
- AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan Fri, 03 Apr 2026 22
- AEON's Botox biosimilar matched 3,400 amino acids as FDA mapped next steps - Stock Titan Mon, 30 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
16.30
-41.41%
|
27.82
-42.55%
|
48.43
+31.31%
|
36.88
|
| Research And Development |
|
4.09
-71.13%
|
14.18
-59.20%
|
34.75
+35.08%
|
25.73
|
| Selling General And Administration |
|
12.21
-10.52%
|
13.64
-0.23%
|
13.68
+22.61%
|
11.15
|
| Total Expenses |
|
16.30
-41.41%
|
27.82
-42.55%
|
48.43
+31.31%
|
36.88
|
| Operating Income |
|
-16.30
+41.41%
|
-27.82
+42.55%
|
-48.43
-31.31%
|
-36.88
|
| Total Operating Income As Reported |
|
-12.80
-117.54%
|
72.98
+250.71%
|
-48.43
+26.45%
|
-65.85
|
| EBITDA |
|
-16.22
+41.49%
|
-27.73
+42.67%
|
-48.36
-31.14%
|
-36.88
|
| Normalized EBITDA |
|
-68.66
+29.55%
|
-97.46
-121.78%
|
-43.95
-404.71%
|
-8.71
|
| Reconciled Depreciation |
|
0.08
-19.59%
|
0.10
+42.65%
|
0.07
+2166.67%
|
0.00
|
| EBIT |
|
-16.30
+41.41%
|
-27.82
+42.55%
|
-48.43
-31.31%
|
-36.88
|
| Total Unusual Items |
|
52.43
-24.81%
|
69.73
+1679.12%
|
-4.42
+84.32%
|
-28.17
|
| Total Unusual Items Excluding Goodwill |
|
52.43
-24.81%
|
69.73
+1679.12%
|
-4.42
+84.32%
|
-28.17
|
| Special Income Charges |
|
3.50
-96.53%
|
100.81
|
0.00
+100.00%
|
-28.97
|
| Other Special Charges |
|
—
|
—
|
—
|
28.97
|
| Restructuring And Mergern Acquisition |
|
-3.50
+96.53%
|
-100.81
|
0.00
|
—
|
| Net Income |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Pretax Income |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Other Income Expense |
|
-22.92
-132.82%
|
69.83
+1792.00%
|
-4.13
+78.00%
|
-18.76
|
| Other Non Operating Income Expenses |
|
-75.35
-79420.00%
|
0.10
-67.13%
|
0.29
-96.93%
|
9.41
|
| Gain On Sale Of Security |
|
48.94
+257.47%
|
-31.07
-603.69%
|
-4.42
-655.47%
|
0.80
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Net Income From Continuing Operation Net Minority Interest |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Net Income From Continuing And Discontinued Operation |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Net Income Continuous Operations |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Normalized Income |
|
-91.66
-230.54%
|
-27.73
+42.40%
|
-48.14
-75.27%
|
-27.47
|
| Net Income Common Stockholders |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Diluted EPS |
|
—
|
72.93
+142.39%
|
-172.03
+5.54%
|
-182.12
|
| Basic EPS |
|
—
|
77.74
+145.19%
|
-172.03
+5.54%
|
-182.12
|
| Basic Average Shares |
|
—
|
0.54
+76.88%
|
0.31
+0.00%
|
0.31
|
| Diluted Average Shares |
|
—
|
0.58
+88.52%
|
0.31
+0.00%
|
0.31
|
| Diluted NI Availto Com Stockholders |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
6.84
|
| Current Assets |
|
6.22
|
| Cash Cash Equivalents And Short Term Investments |
|
5.16
|
| Cash And Cash Equivalents |
|
5.16
|
| Cash Financial |
|
5.16
|
| Other Current Assets |
|
1.06
|
| Total Non Current Assets |
|
0.62
|
| Net PPE |
|
0.59
|
| Gross PPE |
|
0.76
|
| Accumulated Depreciation |
|
-0.17
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.26
|
| Machinery Furniture Equipment |
|
0.20
|
| Other Properties |
|
0.24
|
| Leases |
|
0.07
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
159.89
|
| Current Liabilities |
|
13.05
|
| Payables And Accrued Expenses |
|
11.83
|
| Payables |
|
3.96
|
| Accounts Payable |
|
3.39
|
| Current Accrued Expenses |
|
7.87
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.94
|
| Total Tax Payable |
|
0.57
|
| Current Debt And Capital Lease Obligation |
|
0.28
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
0.28
|
| Total Non Current Liabilities Net Minority Interest |
|
146.84
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Other Non Current Liabilities |
|
104.35
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
| Stockholders Equity |
|
-153.04
|
| Common Stock Equity |
|
-153.04
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
0.52
|
| Ordinary Shares Number |
|
0.52
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
381.26
|
| Retained Earnings |
|
-473.60
|
| Treasury Stock |
|
0.00
|
| Minority Interest |
|
0.00
|
| Total Equity Gross Minority Interest |
|
-153.04
|
| Total Capitalization |
|
-153.04
|
| Working Capital |
|
-6.83
|
| Invested Capital |
|
-153.04
|
| Total Debt |
|
0.28
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
0.28
|
| Net Tangible Assets |
|
-153.04
|
| Tangible Book Value |
|
-153.04
|
| Derivative Product Liabilities |
|
42.49
|
| Other Equity Interest |
|
-60.71
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-17.31
+14.71%
|
-20.29
+42.97%
|
-35.58
-25.15%
|
-28.43
|
| Cash Flow From Continuing Operating Activities |
|
-17.31
+14.71%
|
-20.29
+42.97%
|
-35.58
-25.15%
|
-28.43
|
| Net Income From Continuing Operations |
|
-39.22
-193.37%
|
42.01
+179.92%
|
-52.56
+5.54%
|
-55.64
|
| Depreciation Amortization Depletion |
|
0.08
-19.59%
|
0.10
+42.65%
|
0.07
+2166.67%
|
0.00
|
| Depreciation |
|
0.08
-19.59%
|
0.10
+42.65%
|
0.07
+2166.67%
|
0.00
|
| Depreciation And Amortization |
|
0.08
-19.59%
|
0.10
+42.65%
|
0.07
+2166.67%
|
0.00
|
| Other Non Cash Items |
|
19.66
+118.95%
|
-103.74
-2450.69%
|
4.41
-76.26%
|
18.59
|
| Stock Based Compensation |
|
5.32
-14.93%
|
6.25
+6.08%
|
5.89
+12.87%
|
5.22
|
| Asset Impairment Charge |
|
—
|
—
|
0.33
-83.27%
|
1.98
|
| Operating Gains Losses |
|
3.80
-88.95%
|
34.39
|
—
|
—
|
| Gain Loss On Investment Securities |
|
3.80
-88.95%
|
34.39
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
4.42
+655.47%
|
-0.80
|
| Change In Working Capital |
|
-6.94
-1083.14%
|
0.71
-88.74%
|
6.27
+342.66%
|
1.42
|
| Change In Prepaid Assets |
|
1.19
+330.99%
|
-0.51
-677.27%
|
-0.07
-136.26%
|
0.18
|
| Change In Payables And Accrued Expense |
|
-7.17
-752.78%
|
1.10
-83.11%
|
6.51
+416.51%
|
1.26
|
| Change In Accrued Expense |
|
-2.21
-55.02%
|
-1.42
-1255.24%
|
-0.10
-104.87%
|
2.16
|
| Change In Payable |
|
-4.97
-296.99%
|
2.52
-61.86%
|
6.61
+836.41%
|
-0.90
|
| Change In Account Payable |
|
-4.97
-296.99%
|
2.52
-61.86%
|
6.61
+836.41%
|
-0.90
|
| Change In Other Working Capital |
|
-0.95
-893.33%
|
0.12
+168.97%
|
-0.17
-569.23%
|
-0.03
|
| Investing Cash Flow |
|
-0.00
|
0.00
+100.00%
|
-0.31
-80.00%
|
-0.17
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
|
0.00
+100.00%
|
-0.31
-80.00%
|
-0.17
|
| Net PPE Purchase And Sale |
|
-0.00
|
0.00
+100.00%
|
-0.31
-80.00%
|
-0.17
|
| Purchase Of PPE |
|
-0.00
|
0.00
+100.00%
|
-0.31
-80.00%
|
-0.17
|
| Capital Expenditure |
|
-0.00
|
—
|
-0.31
-80.00%
|
-0.17
|
| Financing Cash Flow |
|
20.30
+34.05%
|
15.15
-62.61%
|
40.51
+198.67%
|
13.56
|
| Cash Flow From Continuing Financing Activities |
|
20.30
+34.05%
|
15.15
-62.61%
|
40.51
+198.67%
|
13.56
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
15.00
-62.97%
|
40.51
+170.05%
|
15.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
15.00
-66.29%
|
44.50
+196.67%
|
15.00
|
| Repayment Of Debt |
|
—
|
—
|
-3.99
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
15.00
-66.29%
|
44.50
+196.67%
|
15.00
|
| Long Term Debt Payments |
|
—
|
—
|
-3.99
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
15.00
-62.97%
|
40.51
+170.05%
|
15.00
|
| Net Common Stock Issuance |
|
18.51
+12494.56%
|
0.15
|
—
|
—
|
| Net Other Financing Charges |
|
1.79
|
—
|
—
|
-1.44
|
| Changes In Cash |
|
2.99
+158.17%
|
-5.14
-211.41%
|
4.62
+130.70%
|
-15.04
|
| Beginning Cash Position |
|
0.01
-99.75%
|
5.16
+0.59%
|
5.13
-74.57%
|
20.17
|
| End Cash Position |
|
3.01
+23023.08%
|
0.01
-99.87%
|
9.75
+90.05%
|
5.13
|
| Free Cash Flow |
|
-17.31
+14.69%
|
-20.29
+43.46%
|
-35.89
-25.48%
|
-28.60
|
| Common Stock Issuance |
|
18.51
+12494.56%
|
0.15
|
—
|
—
|
| Issuance Of Capital Stock |
|
18.51
+12494.56%
|
0.15
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 8-K2026-04-03 View
- 10-K2026-03-30 View
- 8-K2026-03-30 View
- 42026-03-11 View
- 8-K2026-03-09 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-02-19 View
- 8-K2026-01-21 View
- 8-K2026-01-12 View
- 8-K2025-12-15 View
- 8-K2025-12-04 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-13 View
- 8-K2025-09-08 View
- 10-Q2025-08-12 View
- 8-K2025-08-12 View
- 8-K2025-06-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|